Bronchodilator safety in chronic obstructive pulmonary disease-reply.
Division of Respirology, Department of Medicine, University Health Network, Toronto, Ontario, Canada3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada4Division of Respirology, Department of Medicine, University of Toronto, Toronto, Onta.
Matthew B
MB
Stanbrook
Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
Michael
M
Campitelli
Division of Respirology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada4Division of Respirology, Department of Medicine, University of Toronto, Toron.
Andrea
A
Gershon
D001993:Bronchodilator Agents / Q000008:administration & dosage*; D018680:Cholinergic Antagonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012602:Scopolamine Derivatives / Q000008:administration & dosage*
D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives